Trial Profile
A randomized, double blind, controlled study of doxorubicin transferrin conjugate [TRF-DOX] in patients with advanced FIGO stage IV ovarian cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2015
Price :
$35
*
At a glance
- Drugs Doxorubicin conjugate (Primary) ; Doxorubicin
- Indications Ovarian cancer
- Focus Therapeutic Use
- 16 Apr 2015 New trial record